Patients taking Novo Nordisk's Wegovy obesity treatment maintained an average of 10% weight loss after four years, ...
Novo Nordisk's (NVO) obesity therapy Wegovy cut adverse kidney-related events by 22% in obese and overweight individuals in a ...
The results shed light on the long-term effects of Wegovy, and could boost Novo Nordisk’s case to insurers and governments to ...
The data could potentially bolster Novo's case for Wegovy as it attempts to convince insurers and governments to cover the ...
Certain genes may identify patients with obesity who are most likely to respond strongly to Novo Nordisk's weight-loss drug ...
The anti-diabetic medication “Ozempic” (semaglutide) made by Danish pharmaceutical company “Novo Nordisk”on February 23 ...
Die Medikamente zur Gewichtsreduktion von Eli Lilly und Novo Nordisk sind in aller Munde. Dabei steht der nächste Blockbuster ...
Amid the growing popularity of drugs used for weight loss like Ozempic, Wegovy, Mounjaro and Zepbound, one question has ...
Novo Nordisk (NVO) claims it retains only 60% of list price of weight loss drugs Ozempic and Wegovy after payments to pharma ...
A recent US study has found that weight loss medications like Wegovy and Ozempic may increase the risk of abdominal paralysis ...
Der Pharmakonzern Novo Nordisk hat im ersten Quartal dank der hohen Nachfrage nach seinen Appetitzüglern einen Umsatz- und Gewinnsprung verzeichnet. So stieg der Umsatz um 22 Prozent auf 65,35 ...
London, 02. Mai (Reuters) - Der dänische Pharmakonzern Novo Nordisk profitiert weiter vom Boom seiner Abnehmmedikamente und hat die Prognose für 2024 angehoben. Für den Umsatz rechnet der ...